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Abstract
Based on available metabolomic studies, influenza infection affects a variety of
cellular metabolic pathways to ensure an optimal environment for its replication and
production of viral particles. Following infection, glucose uptake and aerobic
glycolysis increase in infected cells continually, which results in higher glucose
consumption. The pentose phosphate shunt, as another glucose-consuming
pathway, is enhanced by influenza infection to help produce more nucleotides,
especially ATP. Regarding lipid species, following infection, levels of triglycerides,
phospholipids, and several lipid derivatives undergo perturbations, some of which
are associated with inflammatory responses. Also, mitochondrial fatty acid β-
oxidation decreases significantly simultaneously with an increase in biosynthesis of
fatty acids and membrane lipids. Moreover, essential amino acids are demonstrated
to decline in infected tissues due to the production of large amounts of viral and
cellular proteins. Immune responses against influenza infection, on the other hand,
could significantly affect metabolic pathways. Mainly, interferon (IFN) production
following viral infection affects cell function via alteration in amino acid synthesis,
membrane composition, and lipid metabolism. Understanding metabolic alterations
required for influenza virus replication has revealed novel therapeutic methods based
on targeted inhibition of these cellular metabolic pathways.
Keywords: Influenza, Glycolysis, Fatty acid synthesis, Metabolism, Indoleamine-2,3-
dioxygenase
Background
Influenza virus infection (IVI) is one of the most common infectious agents, capable of
infecting a variety of avian and mammalian species. The virus is responsible for seasonal
epidemics, leading to 3–5 million severe infections and 250,000–500,000 deaths annually
[1, 2]. Despite the annual vaccination program, the high mortality rate caused by
influenza infection and its various complications, including chronic lung disease, cardiac
disease, asthma, and metabolic disorders, is yet to be adequately addressed [3–5].
In 1956, Eagle et al. first indicated that the addition of glucose to HeLa cell medium
could promote the generation of poliovirus progeny [6]. Results of a published study
showed that the replication of the influenza virus depends on host cellular metabolism
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such that metabolites including nucleic acids, proteins, glycoproteins, and lipids are
crucially required for the life cycle of the influenza virus [7]. Recent research on a
mouse model showed that influenza infection could affect more than 100 metabolite
markers in serum, lung, and bronchoalveolar lavage fluid [8]. Acquiring the required
materials from the host cell to self-replicate, the virus can disrupt biochemical pro-
cesses such as glycolysis, fatty acid (FA) synthesis, and glutamine pathways [9]. It is of
particular importance for scientists to broaden their horizon on the metabolic changes
during influenza infection, which in turn paves the way for preventing life-threatening
consequences.
Influenza infection actively provokes the pro-oxidant condition in the host cell to facili-
tate viral proliferation and pathogenesis. Increased expression of influenza M2 protein
can activate protein kinase C and increase reactive oxygen species (ROS) production [10].
On the other hand, PB1-F2 decreases superoxide anion dismutase 1 (SOD1) expression
and consequently disrupts the ROS scavenging process [11]. In people with influenza in-
fection, increased levels of DNA, lipid, and protein oxidation products are found in
plasma and urine [12–14]. Also, increased levels of ROS and inducible nitric oxide syn-
thase (iNOS) have been observed as markers of oxidative stress in the lungs of people
who died due to pandemic influenza infection [15]. ROS-producing enzymes induced by
influenza infection mainly include NADPH oxidase (Nox) and xanthine oxidase, upregula-
tion of which causes the impaired defensive function of antioxidants [16]. An increase in
ROS production, along with impaired antioxidant function, ultimately leads to a profound
change in redox homeostasis of the cell [16–19]. Nox2 is a phagocytic enzyme that is in-
volved in the production of ROS induced by influenza virus [19–22], and impaired Nox2
expression results in a lack of increased RNS and ROS production following influenza
infection [20]. Xanthine oxidase is also an ROS-producing enzyme that is induced by
influenza infection [23, 24], and its inhibition can hinder ROS increase in the cell.
On the other hand, increased expression of SOD1 reduces influenza virus titers within
the cell [25]. It is also reported that influenza infection significantly increases ROS pro-
duction by inducing Nox4, and the proliferation of this virus in lung epithelial cells is
dependent on redox-sensitive pathways activated by Nox4-derived ROS [16]. Glutathione
(GSH) is a vital antioxidant in the cell, and its cellular content is inversely related to influ-
enza virus replication in the cell [26, 27]. It is indicated that higher levels of GSH, antioxi-
dant enzymes such as glutathione peroxidase, and the anti-apoptotic protein Bcl-2 in the
lungs of female mice result in superior resistance of these mice to influenza infection. In
contrast, male mice are more susceptible to this infection due to higher expression of
Nox4. This difference is due primarily to the higher ability of female mice to maintain cel-
lular redox homeostasis [28]. Amatore et al. also showed that an increase in GSH content
in organs by affecting GSH-dependent antiviral pathways strengthens the immune system,
in particular Th1 cell response, and decreases viral replication [29]. However, GSH deple-
tion results in a deviation of the response towards Th2 cells [30].
Furthermore, oxidative stress following infection can induce the transcription factor
NF-kB, which subsequently leads to increased levels of inflammatory cytokines, including
interleukin (IL)-1β, IL-6, IFN, and TNF [31, 32]. IFNs are one of these cytokines that trig-
ger and affect T cell metabolism via mediating glucose uptake, glycolysis, and lipid synthe-
sis. IFN can also exert its function on metabolic changes by producing several mediators
including indoleamine-2,3-dioxygenase (IDO) and nitric oxide (NO), both of which
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appear to have either an inducible or an inhibitory role in viral replication [33]. Since tryp-
tophan is critical for T cell proliferation, depletion of this amino acid by IDO suppresses
the immune system through the stimulation of T regulatory cells. NO, on the other hand,
inhibits viral replication via changes in the structure of viral proteins [34]. In this review,
we first discuss the metabolic abnormalities during influenza infection and then shed light
on the role of immunometabolites that regulate cellular metabolism. The following
sections summarize recent evidence about the novel therapeutic approaches that target
metabolic pathways in influenza infection.
Metabolic perturbations in influenza infection
Viruses take advantage of various cellular mechanisms to replicate efficiently. Vital meta-
bolic pathways of host cells are one of the most widely used mechanisms targeted by vi-
ruses, resulting in considerable changes. In this context, studies have revealed that various
human viruses, such as cytomegalovirus [35–37], rubella [38, 39], dengue [40], mumps
[41], poliovirus [42, 43] and reovirus [44] can strongly affect host cell glycolysis, lipid me-
tabolism, and glutaminolysis. Furthermore, a review by Sanchez and Lagunoff delineated
the activation of these metabolic processes by several viruses [45]. As will be discussed in
this section, influenza as a highly pathogenic human virus interferes tremendously with
the host metabolic cycles and thereby forces them to produce viral particles more
efficiently.
Glucose metabolism
The metabolism and concentration of glucose in the cell play a cardinal role in the homeo-
stasis of cellular metabolic procedures [46]. Shortly after the onset of IVI, the rate of glucose
uptake by infected cells increases continually, and the subsequently enhanced glycolysis re-
sults in higher glucose consumption, production of viral particles [47, 48], and extracellular
concentration of lactate. The relationship between glycolysis and IVI has shown that influ-
enza infection at a higher multiplicity of infection (MOI) raises the glycolytic activity of the
cells [49]. In a study by Kohio and Adamson, a dose-specific increase in influenza infection
was associated with higher glucose levels, whereas the treatment of cells with glycolysis in-
hibitors remarkably suppressed the viral replication. However, the viral infection could be
retriggered by adding ATP to the cell environment. This study revealed that enhancing
vacuolar-type ATPase (a proton pump essential for influenza uncoating) via increasing glu-
cose metabolism and, as a result, higher available ATP resources, augments the virus infec-
tion [50]. The observations, as mentioned above, reveal a significant increase in ATP and
glucose consumption within cells following influenza infection and also highlight the de-
pendence of the influenza virus on the glycolysis pathway for energy production. The viral
replication has the highest use of ATP during influenza infection, releasing large quantities
of energy in the form of heat. This process can increase the temperature of infected cells by
4–5 °C. As viral proliferation increases, the cellular ATP level drops sharply, resulting in re-
duced potential and stability of the mitochondrial membrane [51]. Based on available re-
sults, patients with metabolic disorders can develop more severe influenza infection
compared to healthy hosts. There have been several studies showing that diabetes can in-
crease the risk of influenza infection, the severity of the disease, and the fatal consequences
of this infection [52–55]. About 90% of patients with type 2 diabetes are overweight, and
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obesity is a significant risk factor for severe influenza infection [56]. This reinforcing effect
of diabetes on influenza may be due to the inhibitory effect of hyperglycemia on the im-
mune system [57–59]. It has been shown that this hyperglycemia-associated immunosup-
pression and susceptibility to influenza infection can be alleviated by insulin administration
and diabetes control [60]. On the other hand, the pentose phosphate pathway (PPP), as an-
other glucose-consuming pathway reported to be enhanced by IVI [61], contributes to a
higher yield of nucleotides and ATP for viral replication [62]. Significant up-regulation of
the PPP key enzymes in influenza-infected cells, including glucose 6-phosphate dehydrogen-
ase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD), was reported by Janke et al.
[63]. G6PD enzyme is also responsible for the generation of NADPH [64], a critical compo-
nent of fatty acid biosynthesis. The level of G6PD activity specifies the ability of the cell to
clear the accumulated ROS. Cells with an average G6PD level can retain the appropriate
GSH/GSSG ratio and keep the ROS production at a tolerably low level, indicating that
G6PD activity has an inverse correlation with cellular ROS level [65]. Disruption of redox
balance has been shown to contribute to replication and virulence of several viruses [66–
68], and G6PD deficiency can cause this disruption. Despite the results reported by Janke
et al., G6PD activity seems to have an inverse relation with some other respiratory viral in-
fections. For example, in an in vitro study, after infection with human coronavirus (HCoV)
229E, the production of viral particles in G6PD-deficient or G6PD-knockdown cells was
higher than in healthy cells, and this was correlated with increased oxidant production [67].
Molecular mechanisms through which the virus can control the metabolic pathways
have been thoroughly identified. Smallwood et al. have shown that an increase in glu-
cose uptake, glycolysis, and glutaminolysis following influenza infection may be related
to the loss of PI3K/AKT/mTOR pathway homeostasis and subsequent increase in c-
Myc expression in the infected cells [9]. Regarding the available results, the mechanistic
target of rapamycin complex 1 (mTORC1) and mTORC2 signaling can be activated by
a variety of influenza virus proteins. The viral hemagglutinin (HA) protein, along with
virus replication, can upregulate PDPK1-mediated phosphorylation and activate AKT,
which is required for induction of the mTORC1 signaling pathway by the influenza
virus. On the other hand, influenza M2 protein is capable of down-regulation of the
mTORC1 inhibitor REDD1, thereby enhancing the mTORC1 activation [69]. mTORC1
signaling, in turn, promotes c-Myc expression at the translational level [70]. Addition-
ally, the NS1 protein can effectively promote the activity of mTORC2, which, in turn,
upregulates c-Myc through FoxO inhibition [71]. Moreover, AKT-dependent inactiva-
tion of FoxOs can increase glycolysis [72, 73] by removing the suppressive force of c-
Myc [74–76]. Myc enhances glycolysis by upregulating expression of the glucose trans-
porter GLUT1, glycolytic genes, and lactate dehydrogenase (LDH), as the converter of
pyruvate to lactate [77, 78]. mTORC1 also mediates upregulation of hypoxia-inducible
factor-1α (HIF-1α), a factor that increases the expression of various genes [79], includ-
ing several glycolytic enzymes, glucose transporters, and LDH [80–82]. AKT is able to
promote the expression and membrane localization of GLUT1 as well as the function
of phosphofructokinase [83, 84]. Furthermore, AKT is demonstrated to activate SREBP
in an mTORC1-dependent manner [85] and to upregulate SREBP by enhancing the sta-
bility of its processed form [86]. SREBP1 is shown to be required for the mTORC1-
induced increase in the expression of G6PD, which is the rate-limiting enzyme of the
PPP oxidative branch [79].
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In addition to the above-mentioned metabolic pathways, the influenza virus exhibits dis-
ruptive effects on some other metabolic processes, which gives rise to metabolic disorders
and ATP crisis. Previous studies have found that the influenza infection increases the cel-
lular synthesis of fatty acids [87], with some of their derivatives, including eicosanoids
[88], and these molecules are natural endogenous ligands and stimulators of peroxisome
proliferation-activated receptors (PPARs) [88–90]. PPARs are a group of nuclear receptor
proteins that act as transcription factors and regulate the expression of different genes
[91] involved in cellular differentiation and metabolism of carbohydrates, lipids, and pro-
teins [92]. Furthermore, all types of PPARs discovered so far are able to suppress the ac-
tivity of the pyruvate dehydrogenase (PDH) enzyme (known as a catalyzer of the oxidative
decarboxylation of pyruvate leading to acetyl-CoA production) in various organs through
the upregulation of pyruvate dehydrogenase kinase (PDK)-4 [93]. In this respect, ex-
tremely low PDH enzyme activity has been found after influenza infection in vitro.
Enhanced PDK4-mediated inhibition of PDH has been found in the lung tissue of
influenza-infected mice. This enzyme inhibition contributes to an erroneous process,
which causes significant disruption of glucose oxidation, cellular respiration, and lipid
metabolism (Fig. 1) [7, 94].
Lipid metabolism
Following infection, levels of phospholipids and several lipid derivatives undergo perturba-
tions. Several lines of evidence have shown that in obese mice due to abnormalities in the
Fig. 1 Metabolic changes caused by influenza infection and related mechanisms. Several anabolic and
catabolic processes can be affected: higher glucose uptake and metabolism in glycolysis and pentose
phosphate pathways, higher nucleotide catabolism, increase in biosynthesis of fatty acids including
arachidonic acid, the precursor of proinflammatory lipids, and also enhanced glutaminolysis and protein
synthesis. Activation of mTORC1&2 signaling and downstream factors by influenza infection may have an
essential role in the upregulation of these metabolic processes. In addition, high ATP consumption and
reduced β-oxidation, as well as glucose oxidation by influenza infection, contribute to the ATP crisis and
hence influenza-related multi-organ failure
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metabolism of fatty acids and phospholipids, induction of influenza infection produces a
more severe inflammatory response in comparison with non-obese mice [95]. These find-
ings indicate a direct link between influenza-mediated inflammation and the abundance
of lipids and their metabolism in the body. According to a study, diacyl glycerophospho-
choline (PC) and diacyl glycerophosphoethanolamine (PE) species (containing 20:4 or 22:
6 as precursors of docosahexaenoic acid (DHA) and arachidonic acid (AA) respectively)
are associated with influenza-related diseases. Interestingly, glycerophospholipid species
(PC (18:1/20:4) and PC (16:0/22:6)) yields increase during the influenza infection. In
addition, upsurge in PC (18:1/20:4) and PE (18:0/22:4) species is associated with tissue le-
sions in the lungs and trachea. Several phospholipids containing 20:4, especially PC (18:1/
20:4), serve as AA reservoirs in cells, breakdown of which increases the cellular levels of
AA [96]. This influenza-mediated elevation of AA, consistent with inflammation, has also
been reported in the same study [97]. The accumulation of the above-mentioned proin-
flammatory lipids in the cell leads to the promoted synthesis of eicosanoids and inflamma-
tory mediators, thus exacerbating post-infection necrosis, inflammation, and tissue
damage in the lungs [96]. In a prospective cohort study on influenza-infected subjects,
lipid inflammatory mediators in serum samples of patients were mainly AA-derived oxyli-
pins, including TXB2, 15-deoxy-12,14-PGD2, 20-HETE, 5,6-DHET, 5-oxoETE, LTE4, and
12-HpETE. Although all of these metabolites were shown to be elevated shortly after the
infection, 5,6-DHET and 5-oxoETE levels remained considerably high up to 4 weeks post-
infection, indicating a constant pulmonary inflammation [98].
The pulmonary surfactant system, which is involved in suppressing influenza infection in
the respiratory tracts [99], can be disrupted due to significant influenza-induced changes in
the abundance of different types of PC and PE species as the major components of surfac-
tants [96, 100]. Tanner et al. proposed a principal correlation between influenza replication
and choline lipids metabolism. They found an IVI-mediated reduction in ester-linked PC
species as well as an increased level of sphingomyelin (SM) [101], probably connected with
expending cellular choline stores for SM synthesis. This led to an increase in SM species
within the infected cell. SM and short-chain fatty acid-containing ether-linked PC (ePC)
species were found in higher amounts in both infected cells and virions and therefore
appeared to be involved in viral morphogenesis. On the other hand, long-chain fatty acid-
containing ePC was increased in infected cells while having low levels in the structure of the
virion, highlighting the role of this phospholipid in replication of the virus [101].
Evidently, higher production of these complex lipids in the cell will require increased
biosynthesis of fatty acids. In this regard, the results of a study revealed that influenza
infection could induce fatty acid biosynthesis and cholesterol metabolism in human
lung basal epithelial tumor cells [87]. Since SREBPs are thoroughly identified as stimu-
lators of expression of many genes involved in lipid and sterol biosynthesis, including
fatty acid synthase [102–104], their upregulation by the influenza virus (through induc-
tion of mTORC1 signaling, as discussed earlier) may logically explain the increased rate
of lipogenesis [105]. A coincidence between increased fatty acid synthesis and a decline
in fatty acid β-oxidation has been found during influenza infection, which is attributed
to a variety of mechanisms directly or indirectly related to viral replication. For in-
stance, the sharp increase of proinflammatory cytokines during influenza infection
[106] causes decreased hepatic fatty acid β-oxidation both in vitro and in vivo [107,
108], most likely through excessive nitric oxide and other related free radicals [109]. In
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addition, increased temperature of cells during infection (which could be the result of
virus replication and fever) causes heat stress which in turn can considerably downreg-
ulate carnitine palmitoyltransferase II (CPT II) activity and reduce the β-oxidation and
ATP levels in fibroblasts of influenza-associated encephalopathy patients and healthy
volunteers [110]. A study on influenza-infected mice demonstrated a significant depres-
sion in long hepatic chain fatty acid β-oxidation at both the mRNA and protein level,
as several β-oxidation essential enzymes were reduced by > 50% [97]. A significant de-
crease in mitochondrial fatty acid β-oxidation simultaneously with increased biosyn-
thesis of fatty acids and membrane lipids may reflect the fact that the virus stores
structural lipids to produce more infectious particles. In addition to impaired metabol-
ism in mitochondria, influenza infection induces severe peroxisomal lipid metabolism
disorders, which can be inferred from abnormal levels of several specific long-chain
fatty acids [101] (Fig. 1).
Other metabolites
The aforementioned metabolic processes are not the only pathways affected by influ-
enza virus infection. This virus has the ability to induce higher consumption rates of
glutamine during glutaminolysis, which can be attributed to transient c-Myc overex-
pression [9]. Myc acts to regulate glutamine uptake and its utilization in the cell [111].
It has been demonstrated that catalytic activity of glutaminase, as the key enzyme in
glutaminolysis, greatly increases following the infection [63]. Moreover, essential amino
acids, especially tryptophan, are other materials whose quantities have been shown to
decline in infected tissues [112]. mTORC1 can up-regulate protein synthesis through
several downstream factors [113]. Thus, induction of mTORC1 signaling by the influ-
enza virus leads to higher usage of essential amino acid storages for concurrent produc-
tion of large amounts of viral and cellular proteins. Infection of influenza virus can also
alter the cellular level and metabolism of purines and pyrimidines [8, 98, 100], and is
associated with both increased activities of nucleotide catabolism core enzymes includ-
ing adenosine deaminase (ADA) and xanthine oxidase (XO) and elevated levels of in-
osine, hypoxanthine, xanthine, and uric acid in serum and bronchoalveolar lavage fluid.
Enhanced catabolic degradation of nucleotides and their metabolites can facilitate the
production of superoxide and contribute to the pathogenesis of influenza infection
[23].
Immunometabolites and their role in influenza infection
Interferons are well-known cytokines with a powerful capability of altering the cellular
functions following viral infections. These alterations affect protein synthesis, compos-
ition of the membrane, cellular proliferation, and nutritional status [34]. Interferon
stimulated genes (ISGs) are the effector components whose transcription could be in-
duced by type I IFNs and IFNγ [114, 115].
IFNs and energy metabolism
Studies have recently underscored the general effect of IFNs on the energy metabolism
of cells, mostly by promoting glycolysis. For instance, IFNβ has been shown to induce
the glucose uptake of embryonic fibroblasts in a PI3/AKT-dependent manner, thereby
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increasing ATP production [116]. It has also been demonstrated that type I IFN can
stimulate oxygen consumption in a range of cells, including conventional dendritic cells
(DCs), keratinocytes, and memory T cells [117]. Indeed, the high yield of ATP and mito-
chondrial fitness guarantee the host cell’s need for energy in plasmacytoid DCs (pDCs)
and non-hematopoietic cells following challenges with viral pathogens [118]. These stud-
ies emphasized the mediatory effect of type I IFN on glycolysis induction via IFNAR1,
Tyk2, and STAT1. It has also been shown that influenza infection stimulates pDCs to en-
hance their glycolysis and develop a Warburg-like remodeling of energy metabolism. This
enhanced glycolysis leads to higher IFN production and, consequently, more potent anti-
viral activity [118]. IFNγ induces metabolic reprogramming of M1 macrophages as a rapid
increase in aerobic glycolysis, followed by a reduction in oxidative phosphorylation. This
metabolic reprogramming maintains cell viability and the inflammatory response while
reducing dependence on mitochondrial oxidative metabolism. Excessive production of
pro-inflammatory cytokines and chemokines in human monocytes/macrophages can be
blocked by inhibition of aerobic glycolysis [119]. Also, activation of macrophages by IFNγ
induces expression of the ATP-citrate lyase enzyme (ACLY), and blockage of ACLY activ-
ity reduces the production of ROS and nitric oxide [120].
There is a strong consensus that influenza replication is crucially dependent on fatty
acids [97], which makes it a fascinating target for therapeutic modalities [45]. Thus, the
ability of IFN to channel the FAs from biosynthesis to catabolism via fatty acid oxida-
tion (FAO) is currently known as a promising antiviral strategy in pDCs [117], which
requires further research for more elucidation. Several lines of current evidence have
revealed the antiviral activity of type I IFN to be exerted through hampering glucose-
derived cholesterol and fatty acid synthesis [121, 122]. Sterol regulatory binding protein
2 (SREBP2), along with SREBP1, is known as the leading transcription factor which or-
chestrates the biosynthesis pathway of sterol, whose inhibited transcription and expres-
sion can be strongly mediated by IFNs via IFNAR1 [123] (Fig. 2).
Innate immune cells can recognize influenza A viruses and their infected cells by
toll-like receptors (TLRs) [124]. This recognition can lead to the induction of an in-
flammatory response that, in turn, controls the replication and spread of the virus [31].
H5N1, H7N7, and H7N9 were correlated with increased transcription of the cytokine
response in mice. Severe infection with H7N9, H7N7, H5N1, or 1918 virus can lead to
upregulation of inflammatory cytokine genes along with downregulation of lipid metab-
olism and coagulation genes [125]. This uncontrolled proinflammatory response ac-
companied by an inadequate anti-inflammatory response is referred to as the cytokine
storm [31]. Monocytes/macrophages, neutrophils, and lung epithelial cells have useful
roles in the cytokine storm developed by influenza infection [126]. Severe cytokine
storm, with greater levels of interferons and tumor necrosis factors, has been recog-
nized in patients hospitalized due to influenza infection [127]. Such influenza-induced
cytokine storms, together with viral virulence, can develop severe lung injury in patients
[128, 129]. It is believed that the level of the cytokine storm is directly associated with
the severity of the disease caused by influenza infection [130, 131]. Some specific poly-
morphisms in immune system genes have determinative roles in the outcome of influ-
enza infection. Our previous studies have shown a relationship between cytokine gene
polymorphisms and severity of the influenza disease. Several cytokines were evaluated
after influenza A/H3N2 virus infection, among which IL-17 rs2275913 GG and AG,
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GG and GT of IL-10 (rs1800872) and IL-28 (rs8099917) genotype TT polymorphisms
were associated with increased risk of influenza infection.
In contrast, IL-1β (rs16944) (GG) and IL-28 (rs8099917) GG and TG genotypes were
associated with reduced risk of infection [132]. In another study, an association be-
tween IL-1β rs16944 and IL-17 rs2275913 genotypes and severe influenza disease was
found while IL-10 rs1800872 and IL-28 rs8099917 polymorphisms were not associated
with influenza disease. Also, lacking an A allele in IL-17 rs2275913 could increase the
risk of influenza A (H1N1) infection [2]. Such polymorphisms in immune system genes
may be associated with some metabolic changes and, in turn, may reinforce the meta-
bolic disorders following influenza infection. However, additional studies are needed in
this field to confirm or reject this opinion.
IFNs and amino acid metabolism and the role of IDO
IFNs are known to be capable of depletion of polyamines to limit virus replication.
Polyamines are small ornithine-derived polycationic molecules which encompass three
molecules: putrescine, spermidine, and spermine. Spermidine and spermine depletion is
one of the compelling mechanisms through which IFNs produce their antiviral effects
on the replication of RNA viruses. Mechanistically speaking, polyamines appear to play
a pivotal role in the processes of RNA transcription and protein translation of viruses,
making them a promising target to combat viral infections [133].
L-tryptophan is one of the nine essential amino acids with a remarkable role in im-
munosuppression and tolerance and is also essential in protein, kynurenine, and sero-
tonin synthesis [122]. IDO is an intracellular enzyme that induces production of
Fig. 2 Role of IFNs in host cell metabolic changes following infection with influenza. IFNs affect the lipid
metabolism through downregulation of SREBP-2, leading to higher cholesterol biosynthesis, and suppressed
host cell apoptosis and PGE-2 production. They can also enhance the level of 25-HC arisen from cholesterol
(via activation of Chol-25 hydroxylase) and IDO. SAT-1 can be upregulated by IFNs, lowering the levels of
spermidine and spermine and thereby dampening influenza replication
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kynurenine from L-tryptophan, thereby acting to deplete tryptophan and modulate the
immune system following viral infections [134]. Having two IFN-stimulated response
elements and three IFNγ-activated sites in the promoter of IDO, IFNγ acts as the most
powerful inducer of IDO1 expression [135]. IDO has also been shown to be expressed
during influenza infection [136]. Dendritic cells, macrophages, and epithelial cells can
express IDO [137, 138], and since the primary target for replication of influenza is pri-
marily found to be respiratory epithelial cells, understanding the role of IDO during in-
fluenza infection is of particular importance. There exists a coincidence of peak IDO1
and IFN-k expression during influenza infection. Also, mouse lung airways considerably
express IFN type I and III following infection with influenza [139]. These findings
emphasize that there is upregulated expression and enhanced function of IDO during
influenza infection, which is found to be induced by IFN-I. Moreover, IFN-I is thought
to signal the adjacent cells via IFN-IR and stimulate them to produce IDO [140].
Nonetheless, the IFN-mediated IDO induction during influenza infection gener-
ally has undesirable consequences and establishes immune tolerance [136]. Indeed,
an inhibitory effect of tryptophan depletion on T cell responses has been con-
firmed. Also, IDO induces kynurenine derivation from tryptophan, leading to
stimulation of regulatory T cells [141].
Nowadays, IDO is hypothesized to be part of the “metabolic, immune regulation,”
which plays a protective role in immune responses and inhibits the overreaction of
these responses against influenza infection. A pleiotropic role has been attributed to
IDO during infections, which gives rise to the opposing outcomes (Fig. 3) [142].
Research on the role of IDO in influenza infection has been mainly focused on the murine
models of influenza infection, emphasizing the increased IDO activity and its maximum
expression correlated with increased lymphocyte numbers in the respiratory tract [143].
Fig. 3 Role of IFN in IDO activation. IFNs also induce activity of IDO, an enzyme that mediates the
production of kynurenine from tryptophan. This event results in tryptophan depletion, which in turn
develops the immune tolerance and generates Tregs
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IFNs and nitric oxide induction
Nitric oxide (NO) is a gaseous free radical with accessible vasodilatory and microbicidal
functions [144]. However, the antiviral effect of NO has also been documented, leading to
reduced viral load and more efficient clearance of infection [145]. Nitrosylation of viral
molecules has been offered as an antiviral mechanism employed by NO [146]. Also, NO
synthase-mediated generation of NO leads to the depletion of L-arginine, thereby redu-
cing the level of polyamines. Thus, IFN-induced NOS2 represents antiviral activities, and
this, in turn, may exhibit another mechanism through which IFNs hinder viral infections
such as influenza [34]. Despite existing data regarding the antiviral activity of NO, many
studies have considered NO as a double-edged sword with both pathogenic and viricidal
effects. The role of NO in the pathogenesis of pneumonia caused by influenza virus infec-
tion has been described in mice. The IFNγ response induces greatly increased levels of
iNOS in the lungs of infected mice, leading to the production of a significant amount of
NO and peroxynitrite species, which are among the most important pathogenic factors in
influenza virus-induced pneumonia in mice [147]. Uetani et al. also observed overexpres-
sion of the iNOS gene in human airway epithelial cells induced by influenza A virus infec-
tion [148]. In addition, NO produced by phagocytic cells has antiviral activity that is
simultaneous with nonspecific damage of host cells and viral pathogenesis [149]. In a sur-
vey by Nin et al. on pandemic A/H1N1 influenza infection, all cases showed increased
levels of iNOS protein, tyrosine nitration, and oxygen free radicals, indicating the produc-
tion of peroxynitrite. Their results revealed the involvement of oxidative and nitrative
stress in the pathogenesis of H1N1 influenza virus-induced acute respiratory distress syn-
drome (ARDS) [15]. Influenza-induced cytokines such as IFNγ stimulate NO release from
human airway epithelial cells [150–152]. As mentioned previously, the influenza infection
induces upregulation of HIF-1α.
Interestingly HIF-1α-knockout macrophages show decreased expression of iNOS
after IFNγ stimulation [153], indicating the possible involvement of HIF-1α in influenza
pathogenesis. It has been shown that infection of H5N1 and 1918 viruses induces
higher levels of NO in mice compared to the seasonal H1N1 virus and, as a result, they
develop more intense pathogenic outcomes, while mice with iNOS deficiency showed
reduced morbidity, mortality, and cytokine production in the lungs following H5N1
and 1918 virus infection. Also, systemic administration of NOS inhibitor could post-
pone weight loss and death among 1918 virus-infected mice [154]. In another survey,
the delivery of NO to influenza-infected mice could not improve the lung infection and
survival of mice, indicating that NO administration was not a suitable treatment strat-
egy for influenza although this was probably due to the difficulty of determining con-
centrations of NO that are both viricidal and safe in host airways [155]. Also, it is
reported that NO released from S-nitroso-N-acetylpenicillamine (SNAP) reduces the
replication of influenza virus in a dose-dependent manner. The production of NO in
airway epithelial cells can lead to antiviral rather than harmful effects following influ-
enza infection provided that its production is precisely controlled [156].
Novel therapeutic approaches by targeting metabolic pathways
Since the influenza virus affects about 20% of the world population annually, preventive
and therapeutic approaches require much closer attention. Therapeutic drugs for
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influenza infection fall into three groups: 1) neuraminidase inhibitors (zanamivir, osel-
tamivir, laninamivir, peramivir), 2) M2 inhibitors (rimantadine and amantadine), and 3)
polymerase inhibitors (favipiravir) [157, 158]. Antiviral drug resistance has recently
emerged as a global problem which can bring about a remarkable financial and social
burden [159]. Therefore, further research is urgently needed to develop novel and
promising antiviral drugs. Many of the metabolic pathways in influenza infections are
increasingly changing, dampening of which appears to hamper the virus replication.
One of the newly developed strategies aiming to hinder influenza infection is targeting
metabolic pathways and restoration of hemostasis in cells (Table 1).
The PI3K/mTOR signaling pathway has been shown to play a pivotal role in a variety of
cellular pathways, including proliferation and nutrient uptake, and its activation increases
the glucose uptake through the up-regulation of cell surface glucose transporter [163].
BEZ235 alters glucose metabolism via blockage of the PI3K/mTOR pathway, and some
clinical trials are underway to assess this strategy in cancer therapy (Smith et al., 2012).
On the other hand, several lines of evidence have demonstrated that siRNA targets the
PI3K-AKT-mTOR pathway, thereby warding off influenza infection [164]. In a new study
by Smallwood et al., it was found that although BEZ235 did not interfere with the early
stages of the infection, it could finally reduce the viral progeny and result in prolonged
survival in mice challenged by the influenza virus. Indeed, BEZ235 induced hemostasis in
the PI3K/mTOR pathway via phosphorylation of p85 and 4E-BP1 and through reconstitu-
tion of metabolic status, which was already altered by the virus [9].
It has been found that there is an elevated level of PDK4 in lung, liver, and heart during
influenza infection, while the levels of ATP and PDH, a key enzyme in the regulation of glu-
cose, lipid and ATP levels in human cells, are shown to be reduced [156]. Furthermore,
dichloroacetate (DCA) is a pyruvate dehydrogenase kinase inhibitor with anti-tumor activity
in a variety of carcinomas. Studies have also indicated that diisopropylamine dichloroacetate
(DADA) could ameliorate the metabolism of hepatocytes in chronic liver disease [165]. In a
study by Yamane et al. attempting to evaluate the effect of DADA on influenza-infected
mice (PR8), oral administration of DADA was found to not only restore the activity of PDH
and ATP in affected organs but also suppress cytokine storm and viral replication [94].
Table 1 Characteristics of some metabolic pathway blockers in influenza infection
Agent Target Outcome Model Reference
BEZ235 PI3K/mTOR Reconstitution of metabolic status
and decreased viral replication
In vivo [9]
Hochuekkito Effect on mitochondrial
and glycolysis
Ameliorates metabolism and intensifies
the symptoms
In vitro [160]
Simvastatin Sterol synthesis Decreased influenza replication and
cytokine production
In vitro [161]
DADA Pyruvate dehydrogenase kinase Suppresses cytokine storm and viral
replication
In vivo [94]
MJWQH amino acid, fatty acid and
arachidonic acid pathway
Improved weight loss, lung index,
biomarkers and inflammatory mediators
such as prostaglandin E2
In vivo [162]
Bezafibrate Carnitine palmitoyltransferase II Restores the ATP levels in cells and
intensifies the symptoms
In vivo [110]
AM580 Sterol regulatory element binding
protein (SREBP) pathways
Inhibited influenza virus replication
through interference with SREBP paths
In vivo [105]
DADA Diisopropylamine dichloroacetate, MJWQH Modified Jiu Wei Qiang Huo
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Sterols are intermediate metabolites that play an essential role in a broad spectrum of
biological pathways, including inflammation. Research has shown that interferon pro-
duction following the immune response in viral infection regulates sterol production
paths. Blanc et al. revealed that sterol metabolism pathway regulators such as simva-
statin, Zometa (zoledronic acid), and FPT inhibitor III could effectively hinder H5N1
influenza replication and cytokine production, which makes them promising thera-
peutic candidates in acute patients [121, 161].
On the other hand, as mentioned earlier, SREBPs are transcription factors that have a
critical role in the process of lipogenesis. Studies have shown that these factors can play
a variety of roles, such as energy supply and post-translational protein modification, as
well as in the propagation of various groups of viruses such as influenza viruses. A
study has shown that the AM580 compound, which is a retinoid derivative, inhibits
SREBP-linked pathways, and it has antiviral activity against influenza A and coronavirus
in vitro and in vivo [105].
Concerning the fact that mitochondria and glycolysis are two sources of energy pro-
duction, they play vital roles in the regulation of innate immunity responses. During
the immune system response, and especially the cytokine storm, following influenza in-
fection, ATP synthesis in the mitochondria decreases, leading to weakened innate im-
mune responses (Dengbing Yao). Studies have revealed that traditional herbal
medicines have an important role in improving influenza-like symptoms in infected pa-
tients. Results of a study demonstrated that pre-treatment of infected cells with
Hochuekkito (a traditional Japanese herbal medicine) could activate both mitochondrial
and glycolytic energy metabolism and thereby intensify symptoms [160]. Also, the ef-
fects of traditional Chinese medicine (modified Jiu Wei Qiang Huo) on H1N1 infected
mice were evaluated in another study. The results showed that this herbal medicine
could ameliorate weight loss and inflammatory mediators in infected mice through the
regulation of amino acid, fatty acid, and arachidonic acid pathways [162].
Conclusion
Based on recent studies, influenza virus infection can interfere with cellular metabolic
pathways either directly or indirectly via stimulation of immune system mediators.
Through enhancing the activity of the mTORC1 complex, the influenza virus
strengthens several metabolic pathways, including glycolysis, glutaminolysis, pentose
phosphate, and fatty acid synthesis, to provide more ATP and structural materials for
viral replication. On the other hand, β-oxidation suppression following viral infection
can help to supply essential fatty acids for the synthesis of structural lipids. However,
exhausting cellular ATP resources due to virus replication, as well as an increase in
pro-inflammatory lipid synthesis, will ultimately lead to irreversible cell damage. Innate
immune responses following influenza infection play a crucial role in metabolic alter-
ations. IFN is one of these mediators that acts on several metabolites such as IDO and
NO and thereby affects lipid and amino acid pathways. Since the drug resistance in in-
fluenza infection is a global concern, research on designing novel therapeutic modalities
to tackle pandemics is of particular importance. Thus, a clear understanding of the
metabolic alterations during influenza infection would be tremendously helpful for
therapeutic purposes.
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